NVO stock is either an undervalued gem or a value trap. Let's figure out which. Today, we'll break down the business of Danish drugmaker Novo Nordisk to see why their stock is down nearly 60% from its peak. Is competition from Eli Lilly keeping this European giant down? Or is it simply an execution issue? Or are tariffs wreaking havoc on the company's bottom line? Let's look at all those issues as more to determine if Novo Nordisk stock is a buy now.

Stay informed with our free disruptive technology investing newsletter, Nanalyze Weekly. Sign up now at https://www.nanalyze.com/nanalyze-weekly/. This episode is pulled from a YouTube presentation. View the original presentation at https://youtu.be/_wy8wm9XFm8.